Prescription Drugs - Research and Data from KFF

50-State Survey Finds Slower Growth in Total Medicaid Spending Nationally in FY 2016 and Projected for FY 2017 as Earlier Increases from the Affordable Care Act’s Coverage Expansions Taper Off

Oct 13, 2016

News Release

After record increases in fiscal year 2015, growth in Medicaid enrollment and total Medicaid spending nationally slowed substantially in FY 2016 and are projected to continue to slow in FY 2017 as the initial surge of enrollment under the Affordable Care Act’s coverage expansions tapered off, according to the 16th annual 50-state Medicaid Budget Survey by the…

Spending and Utilization of EpiPen within Medicaid

Oct 7, 2016

Issue Brief

Medicaid is also a major provider of EpiPen and has been impacted by its increasing price. In this Data Note, we examine utilization, spending before rebates, and spending per prescription of EpiPen and other epinephrine auto-injectors before rebates in the Medicaid program.

Snapshot of Where Hillary Clinton and Donald Trump Stand on Seven Health Care Issues

Oct 6, 2016

Issue Brief

Where do the 2016 Presidential candidates, Hillary Clinton and Donald Trump, stand on key health care issues? This snapshot outlines the candidates' positions and policy statements on issues such as health insurance, the ACA, Medicaid, Medicare, the opioid epidemic, prescription drug costs, women's reproductive health, and Zika.

The 16th Annual Kaiser 50-State Medicaid Budget Survey: Slowing Growth and Evolving Policies at a Forum with the National Association of Medicaid Directors

Event Date: Oct 5, 2016

Event

At 9:30 a.m. ET on Thursday, Oct. 13, the Kaiser Family Foundation’s Commission on Medicaid and the Uninsured (KCMU) released Kaiser's 16th annual 50-state Medicaid budget survey for state fiscal years 2016 and 2017.

Web Event: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs

Event Date: Oct 5, 2016

Event

On Wednesday, October 5, from noon to 1 p.m. ET, the Kaiser Family Foundation will host a web conversation to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted.

Kaiser Health Tracking Poll: September 2016

Sep 29, 2016

Report

The September Kaiser Health Tracking Poll takes a look at the public's attitudes on several major health policy issues including prescription drugs costs and the ACA. In addition, the poll explores how important health care issues are to voters during the 2016 presidential election.

Large Majorities Favor Wide Range of Policy Changes to Curb Prescription Drug Costs, Including Those That Give Government a Greater Role in Negotiating or Limiting Prices

Sep 29, 2016

News Release

Amid news reports about increases in the price for EpiPen and other drugs, the vast majority of Americans – including majorities of Democrats, Republicans and independents – support several policy changes to control the cost of prescription drugs, including some that would expand government’s role in drug pricing, the latest Kaiser Family Foundation tracking poll…

Medicare Part D Spending on the EpiPen Increased More than 1000 Percent from 2007 to 2014

Sep 21, 2016

News Release

As policymakers in Washington scrutinize the rising cost of the EpiPen auto-injector, a new analysis from the Kaiser Family Foundation shows that Medicare Part D spending for the potentially life-saving device increased by more than 1000 percent between 2007, the year after the Part D drug benefit took effect, and 2014, the most recent year…

Few People Switch Medicare Advantage Plans Each Year, Raising Questions About Whether Seniors Have the Tools and Information They Need To Compare Plans

Sep 20, 2016

News Release

A small share of Medicare Advantage enrollees switch plans each year, but those who do tend to pick plans with lower premiums and out-of-pocket limits than the plans they left behind, according to a new analysis by the Kaiser Family Foundation.

How Much Has Medicare Spent on the EpiPen Since 2007?

Sep 20, 2016

Issue Brief

This data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: Prescription Drugs

Filter